Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • Bitcoin USD

    64,196.17
    +980.32 (+1.55%)
     
  • CMC Crypto 200

    1,383.48
    +70.86 (+5.40%)
     
  • S&P 500

    4,958.64
    -52.48 (-1.05%)
     
  • Dow

    37,886.28
    +110.90 (+0.29%)
     
  • Nasdaq

    15,255.67
    -345.82 (-2.22%)
     
  • Gold

    2,410.50
    +12.50 (+0.52%)
     
  • Crude Oil

    83.07
    +0.34 (+0.41%)
     
  • 10-Yr Bond

    4.6170
    -0.0300 (-0.65%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson

RLI Corp. (RLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

For Immediate Release

Chicago, IL – April 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeTandem Diabetes Care, Inc. TNDM, Addus HomeCare Corporation ADUS, Tailored Brands, Inc. TLRD, Tellurian Inc. TELL and Johnson & Johnson JNJ.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Wall Street Brushes Off Trade War Fears: Top 5 Gainers

Major bourses made a remarkable comeback on Apr 4, with the Dow Jones gaining more than 700 points from trough-to-peak. Initially, the bourses had plunged below key technical levels after China retaliated with threats to impose tariffs on a number of American goods.

ADVERTISEMENT

But stocks rebounded after investors gauged that the tariffs threats are merely negotiating tactics and both the sides won’t risk a full-blown trade war. After all, trade conflicts dent corporate profits and impede economic expansion. President Trump also downplayed fears over tariffs announced by both China and the United States.

As trade war worries dissipate and the broader market moves north, investing in stocks making the most of the recovery seems judicious.

Wall Street’s Massive Recovery

The Dow Jones rebounded from 510 points, or 2.1% plunge, to finish the session up about 230 points, or 1% on Apr 4. The blue-chip index, thus, registered its best single-session comeback since Feb 6, when blue chips had slipped 2.33% to end at 2.33%.

The S&P 500 and the tech-heavy Nasdaq staged their biggest intraday turnarounds since Feb 9, when the S&P tumbled 1.9% but ended with a gain of 1.5% and the Nasdaq logged a gain of 1.4% after being down 2.2% on that day.

On Apr 4, the S&P gained 30 points, or 1.2%, while the Nasdaq rose 101 points, or 1.5%, eventually erasing steep opening losses. With such gains, the S&P closed above its 200-day moving average for the second-straight day, indicating encouraging long-term trends. The S&P, in particular, gained in back-to-back sessions for the first time since Mar 9. The Nasdaq, in the meanwhile, ended in the positive territory for the year.

What Led to the Initial Losses?

Concerns about a potential trade war between the United States and China had unnerved investors. China’s Ministry of Commerce plans to impose tariffs on 106 U.S. products, including soybeans and airplanes, affecting $50 billion worth of goods.

American soybean manufacturers are likely to face steep losses, as they export almost $13 billion out of the $20 billion yearly agricultural sales to China. These behemoths have huge business operations in China, thus, their revenues and profits are vulnerable to trade disputes.

China retaliated after the Trump administration levied duties on 1,300 Chinese exports, worth $50 billion. The list includes video monitors, electromagnets used in MRI machines, aerospace products, and machinery. U.S. levied tariffs on China to punish the second-largest economy for theft of trade secrets including software and patents.

Trade War Worries Lessen

But, investors soon realized that the countries do not want a full-blown trade war despite the tit-for-tat tariff threats. After all, a trade war is a big worry for corporate America as its profits will be hurt if trade restrictions are put. It may also deal a heavy blow to economies, resulting in widespread unemployment.

Lest we forget, market pundits expect Q1 earnings results to be quite impressive, while Trump’s economy is in good shape with the jobless rate near a 17-year low. Total earnings for the S&P companies are estimated to improve 16% from the same period last year on 7.4% higher revenues, the highest quarterly earnings growth pace in seven years. Such an uptick will follow 13.5% earnings growth on 8.5% revenue improvement last quarter (read more: Looking Ahead to the Q1 Earnings Season). 

The White House also played down the notion of a trade war. Trump’s chief economic advisor, Larry Kudlow told reporters that he is willing to resolve the trade disputes with minimum hassle.

And when it comes to Trump, we all know that his actions are not as tough as his rhetoric. How can we forget that he was supposed to impose hefty tariffs on foreign steel and aluminum? But, he chose to give exemptions to countries like Mexico, Canada, the European Union, South Korea, Australia, Brazil and Argentina after his top allies threatened retaliation.

Top 5 Winners

Not only did major indices end up more than 1% in the last trading session, but these also have the scope to scale higher on reduced trade war fears. We have, thus, selected five stocks that can make the most of the encouraging trend. These stocks also flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy).

Tandem Diabetes Care, Inc. designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings moved up 73.2% in the last 60 days. The stock’s expected growth rate for the current quarter and year are 92% and 88.9%, respectively. The company yielded a return of 4.8% on Apr 4.

Addus HomeCare Corporation provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company has a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings rose 8.9% in the last 60 days. The stock’s expected growth rate for the current quarter and year are 17.7% and 26.2%, respectively. The company yielded a return of 2.3% on Apr 4.

Tailored Brands, Inc. operates as a specialty apparel retailer in the United States. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings moved up 10.4% in the last 60 days. The stock’s expected growth rate for the current quarter and year are 74.1% and 11.4%, respectively. The company returned 4.4% on Apr 4. You can see the complete list of today’s Zacks #1 Rank stocks here.

Tellurian Inc. develop, own, and operate a natural gas business and to deliver natural gas to customers. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings moved up 11.4% in the last 60 days. The stock’s projected growth rate for the current quarter and year are 78.6% and 62.2%, respectively. The company has yielded a return of 4.3% on Apr 4.

Johnson & Johnson develops, manufactures, and sells various products in the health care field. The company has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings climbed 0.4% in the last 60 days. The stock’s estimated growth rate for the current quarter and year are 9.8% and 11.2%, respectively. The company has yielded a return of 1.6% on Apr 4.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report
 
Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report
 
Tailored Brands, Inc. (TLRD) : Free Stock Analysis Report
 
Magellan Petroleum Corporation (TELL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.